Harbour Investments’s Harvard Bioscience HBIO Stock Holding History

Harbour Investments’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$4K	–	3047
2022 Q3	$4K	Hold	100	–	–	﹤0.01%	2238
2022 Q2	$4K	Buy	+100	New	+$4.51K	﹤0.01%	2238
2021 Q4	$7K	Hold	100	–	–	﹤0.01%	2055
2021 Q3	$7K	Hold	100	–	–	﹤0.01%	2827
2021 Q2	$8K	Buy	+100	New	+$7.07K	﹤0.01%	2844

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Harbour Investments's HBIO Position: Q4 2022 in Review

Harbour Investments sold out of Harvard Bioscience (HBIO) in Q4 2022, closing a stake of 100 shares — an estimated $4K sold.

Harbour Investments first reported a position in HBIO in Q2 2021 and held it in 5 quarters. The position peaked at $8K in Q2 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2022.

Harbour Investments reported no remaining Harvard Bioscience position as of Q4 2022 after selling out during the quarter.
Harbour Investments sold 100 Harvard Bioscience shares in Q4 2022, an estimated $4K.
Harbour Investments first reported a position in Harvard Bioscience in Q2 2021 and held it in 5 quarters.
Harbour Investments's Harvard Bioscience position peaked at $8K in Q2 2021.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2022.

Based on Harbour Investments's 13F filing for Q4 2022, filed 16 Feb 2023.